NCT02907749View on ClinicalTrials.gov

Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 1, 2020

Study Completion Date

July 31, 2020

Conditions
CirrhosisPortal Hypertension
Interventions
DRUG

Spironolactone and carvedilol

Patients are treated with carvedilol in combination with spironolactone.

DRUG

Carvedilol

Patients are treated with carvedilol only.

Trial Locations (1)

20065

Shanghai Tongji Hospital, Tongji University, Shanghai

All Listed Sponsors
lead

Changqing Yang

OTHER

NCT02907749 - Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis | Biotech Hunter | Biotech Hunter